Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
Date | Price Target | Rating | Analyst |
---|---|---|---|
8/19/2024 | $3.00 | Buy | H.C. Wainwright |
6/30/2021 | $5.00 | Buy | HC Wainwright & Co. |
Appoints Shawn Matthews, CEO of DNA Holdings Venture, Inc., and Former CEO of Cantor Fitzgerald, to its Board of Directors Names Thomas McLaughlin and Sara Turken, JD, as Chief Investment Officer and General Counsel, respectively PITTSBURGH, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ:POAI), a leader in AI-driven drug discovery and the first Strategic Compute Reserve leveraging the Aethir ecosystem to democratize access to AI infrastructure, today announced additions to its leadership team and Board of Directors in support of the Company's new digital asset treasury strategy focused on the Aethir (ATH) token. The Company announced today that Shawn Matthews, CEO of
Investment creates the world's first Strategic Compute Reserve Strategy complements Predictive Oncology's AI/ML-driven drug discovery and development activities PITTSBURGH, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. ("Predictive Oncology" or the "Company") (NASDAQ:POAI) today announced the closing of two previously announced private investment in public equity transactions ("PIPEs") totaling approximately $343.5 million to support the Company's adoption of a digital asset treasury strategy focused on ATH, the native utility token of the Aethir ecosystem. The Company raised an aggregate of approximately $343.5 million in the PIPEs from the purchase and sale of (i) an agg
Shawn Matthews, CEO of DNA Holdings and Former CEO of Cantor Fitzgerald, will join the Board of Directors upon the closing of the private placements Predictive Oncology continues to execute on its artificial intelligence and machine learning business to expedite early drug discovery and enable drug development for the benefit of cancer patients worldwide PITTSBURGH, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. ("Predictive Oncology" or the "Company") (NASDAQ: POAI) today announced the pricing of two private placement transactions to support its adoption of a digital asset treasury strategy under which the principal holding will be ATH, the native utility token of the Aet
3 - Predictive Oncology Inc. (0001446159) (Issuer)
3 - Predictive Oncology Inc. (0001446159) (Issuer)
4 - Predictive Oncology Inc. (0001446159) (Issuer)
H.C. Wainwright initiated coverage of Predictive Oncology with a rating of Buy and set a new price target of $3.00
HC Wainwright & Co. initiated coverage of Predictive Oncology with a rating of Buy and set a new price target of $5.00
Litchfield Hills Research initiated coverage of Predictive Oncology with a rating of Buy and set a new price target of $3.00
8-K - Predictive Oncology Inc. (0001446159) (Filer)
PRE 14A - Predictive Oncology Inc. (0001446159) (Filer)
8-K - Predictive Oncology Inc. (0001446159) (Filer)
Appoints Shawn Matthews, CEO of DNA Holdings Venture, Inc., and Former CEO of Cantor Fitzgerald, to its Board of Directors Names Thomas McLaughlin and Sara Turken, JD, as Chief Investment Officer and General Counsel, respectively PITTSBURGH, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ:POAI), a leader in AI-driven drug discovery and the first Strategic Compute Reserve leveraging the Aethir ecosystem to democratize access to AI infrastructure, today announced additions to its leadership team and Board of Directors in support of the Company's new digital asset treasury strategy focused on the Aethir (ATH) token. The Company announced today that Shawn Matthews, CEO of
AIRNA, a biotech company pioneering RNA editing therapeutics to restore the health of patients with rare and common diseases, today announced the appointment of Matthew Hawryluk, Ph.D., MBA, as Chief Business Officer. Dr. Hawryluk brings vast leadership experience in the life sciences sector, with a proven track record of bridging scientific innovation and commercial application. "Matt is a tremendous addition to our leadership team, bringing extensive experience driving collaborations and leading high-performing teams," said Kris Elverum, President and CEO of AIRNA. "Matt joins us at a critical time, as we prepare to bring our first RNA editing therapeutic to the clinic. We have the pote
Company to Host International Roadshow the Week of January 13, 2025 LOS ANGELES, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ:RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, today issued a letter to shareholders from Chief Executive Officer David Weinstein. Dear Shareholders, As we enter the new year, I wanted to update you on the progress we have made in the last two months and further define our trajectory for 2025. Our comprehensive analysis of both businesses and development of a 100-day plan of action has already turned up some hidden value in both businesses and is helping us understand key areas of the business we need to for
PITTSBURGH, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ:POAI), a science driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, and CLIA laboratory, to accelerate oncologic drug discovery and enable drug development, today reported financial and operating results for the quarter ended September 30, 2024, and provided a corporate update. The Company reported a loss from continuing operations of approximately $2.3 million on total revenue of $345,686 for the quarter. Predictive Oncology also announced today that the company's Board of Directors, working with a strategic advisor, has i
PITTSBURGH, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ:POAI), a science driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, and CLIA laboratory, to accelerate oncologic drug discovery and enable drug development, today reported financial and operating results for the quarter ended June 30, 2024, and provided a corporate update. The Company reported a net loss of approximately $3.2 million on total revenue of approximately $0.3 million for the quarter. Q2 2024 and Recent Highlights: Entered biomarker discovery market following compelling results from retrospective ovarian cancer s
PITTSBURGH, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ:POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (CLIA) laboratory and Good Manufacturing Practices (GMP) facility, to accelerate oncology drug discovery and enable drug development, today announced that it will report its financial results for the second quarter ended June 30, 2024 before the markets open on Wednesday, August 14, 2024. The company will host a corporate update conference call and live audio webcast at 8:30 a.m. ET. Live Conference Call & Webcas
SC 13G/A - Predictive Oncology Inc. (0001446159) (Subject)
SC 13G - Predictive Oncology Inc. (0001446159) (Subject)